Methods and compositions for stimulating reepithelialisation during wound healing

Patent metadata

Field	Value
Publication number	US-9241944-B2
Application number	US-201113703923-A
Country	US
Kind code	B2
Filing date	Jun 16, 2011
Priority date	Jun 16, 2010
Publication date	Jan 26, 2016
Grant date	Jan 26, 2016

Abstract

The present invention relates to methods and compositions for stimulating reepithelialization during wound healing. More particularly, the present invention relates to a mmeralocorticoid receptor antagonist or an inhibitor of mineralocorticoid receptor gene expression for use in a method for stimulating reepithelialization of the skin or of the cornea during wound healing.

First claim

The invention claimed is:

1. A method for stimulating reepithelialization of skin of a subject in need thereof, comprising the steps of:
locating a wound on a dermal surface of said subject;
providing to keratinocytes at said wound of said subject a therapeutically effective amount of a mineralocorticoid receptor (MR) antagonist wherein said MR antagonist is selected from the group consisting of epoxy-steroidal mineralocorticoid receptor antagonist compounds and non-steroidal receptor antagonist compounds, wherein said step of providing is carried out during a phase of new tissue formation that includes reepithelialization; and
stimulating reepithelialization of said skin of said subject at said wound site during said phase of new tissue formation.

2. The method of claim 1 , wherein said MR antagonist is selected from the group consisting of drospirenone and eplerenone.

3. The method of claim 1 , wherein said step of providing is carried out by topical delivery or transdermal delivery.

4. The method of claim 3 , wherein said topical delivery is cutaneous.

5. The method of claim 1 wherein said wound is selected from the group consisting of a diabetic foot ulcer, a venous stasis ulcer, and a burn.

6. The method of claim 1 wherein said wound is a site of delayed wound healing selected from the group consisting of an aging defect, a surgical scar, a finger crack after cold exposure, a nail pathology, and a foot blister.

7. The method of claim 1 , wherein said epoxy-steroidal mineralocorticoid receptor antagonist compound is selected from the group consisting of Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, dimethyl ester, (7α,11α,17β), 3′ H-cyclopropa[6,7]pregna-4,6-diene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, γ-lactone, (6β,7β,11α,17β, Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, 7-(1-methylethyl) ester, monopotassium salt, (7α,11α,17β), Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, 7-methylethyl) ester, monopotassium salt, (7α,11α,17β), 3′ H-cyclopropa[6,7]pregna-1,4,6-triene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, γ-lactone(6β,7β,11α), 3′ H-cyclopropa[6,7]pregna-4,6-diene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, methyl ester, (6β,7β,11α,17β), 3′ H-cyclopropa[6,7]pregna-4,6-diene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, monopotassium salt, (6β,7β,11α,17β), 3′ H-cyclopropa[6,7]pregna-1,4,6-triene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, γ-lactone(6β,7β,11α,17β), Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, γ-lactone, ethyl ester, (7α,11α,17β), and Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, γ-lactone, 1-methylethyl ester (7α,11α,17β).

8. The method of claim 1 , wherein said non-steroidal receptor antagonist compound is selected from the group consisting of Dihydropyridines, imidazole carboxamides, pyrrole carboxamides, dibenzosuberanes, 3,3-bisaryl oxindoles, 4-aryl-1,4-dihydropyridines, 3-benzyl indoles, benzoxazinethiones, tetrahydroquinolines, aryl benzoxazinones/thiones, and aryl benzoxazinethiones.

9. A method for stimulating reepithelialization of a cornea of a subject in need thereof, comprising the steps of:
locating a wound on said cornea of said subject;
providing to epithelium at said cornea of said subject a therapeutically effective amount consisting of a mineralocorticoid receptor (MR) antagonist wherein said MR antagonist is selected from the group consisting of epoxy-steroidal mineralocorticoid receptor antagonist compounds and non-steroidal receptor antagonist compounds, wherein said step of providing is carried out during a phase of new tissue formation that includes reepithelialization; and
stimulating reepithelialization of said corneal epithelium of said subject at said wound site during said phase of new tissue formation.

10. The method of claim 9 wherein said wound is selected from the group consisting of a corneal ulcer, a site of corneal erosion or trauma, and a site of a keratoplasty.

11. The method of claim 9 wherein said wound is dry eye.

12. The method of claim 9 , wherein said MR antagonist is selected from the group consisting of drospirenone and eplerenone.

13. The method of claim 9 , wherein said step of providing is carried out by topical delivery or transdermal delivery.

14. The method of claim 13 , wherein said topical delivery is ophthalmic.

15. The method of claim 9 , wherein said epoxy-steroidal mineralocorticoid receptor antagonist compound is selected from the group consisting of Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, dimethyl ester, (7α,11α,17β), 3′ H-cyclopropa[6,7]pregna-4,6-diene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, γ-lactone, (6β,7β,11α,17β), Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, 7-(1-methylethyl) ester, monopotassium salt, (7α,11α,17β), Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, 7-methylethyl) ester, monopotassium salt, (7α,11α,17β), 3′ H-cyclopropa[6,7]pregna-1,4,6-triene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, γ-lactone(6β,7β,11α), 3′ H-cyclopropa[6,7]pregna-4,6-diene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, methyl ester, (6β,7β, 11α,17β), 3′ H-cyclopropa[6,7]pregna-4,6-diene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, monopotassium salt, (6β,7β,11α,17β), 3′ H-cyclopropa[6,7]pregna-1,4,6-triene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, γ-lactone(6β,7β,11α,17β), Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, γ-lactone, ethyl ester, (7α,11α,17β), and Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, γ-lactone, 1-methylethyl ester (7α,11α,17β).

16. The method of claim 9 , wherein said non-steroidal receptor antagonist compound is selected from the group consisting of Dihydropyridines, imidazole carboxamides, pyrrole carboxamides, dibenzosuberanes, 3,3-bisaryl oxindoles, 4-aryl-1,4-dihydropyridines, 3-benzyl indoles, benzoxazinethiones, tetrahydroquinolines, aryl benzoxazinones/thiones, and aryl benzoxazinethiones.

Assignees

• Farman Nicolette
• Behar-Cohen Francine
• Jaisser Frédéric
• Inst Nat Santé Et De La Rech Médicale Inserm
• Assist Publ Hopitaux De Paris
• Univ Paris Descartes

Inventors

• Farman Nicolette
• Behar-Cohen Francine
• Jaisser Frédéric

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P25/02

  for peripheral neuropathies · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61K9/0048

  Eye, e.g. artificial tears · CPC title

• A61K31/00

  Medicinal preparations containing organic active ingredients · CPC title